All News

Both patients and providers should recognize the benefits of early referrals to palliative care.

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

With a median follow-up of 90 months, individuals receiving palbociclib in combination with letrozole had numerically longer OS compared to placebo, but it was not deemed statistically significant.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.

An immune checkpoint inhibitor plus ramucirumab found to improve overall survival versus standard of care in patients with advanced non-small cell lung cancer.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Suzanne Soliman, PharmD, BCMAS, discusses pharmacy management.

Dupilumab is under clinical development, and the efficacy and safety have not been fully evaluated by any regulatory authorities.

Uliledlimab plus toripalimab (Tuoyi) shows significant response rates in patients with advanced non–small cell lung cancer previously ineligible to receive standard-of-care treatment.

The drug is a treatment for individuals who are healing all grades of erosive esophagitis, as a relief of heartburn, and as maintenance of healing all grades of EE and relief of heartburn.

The efforts of pharmacists remain critical to the success of treatment outcomes.

Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.

Improvement in recurrence-free survival was seen primarily in individuals with very high-risk renal cell carcinoma, whereas individuals with intermediate high-risk disease showed no improvements in survival.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

The median overall survival was 66 months for individuals with hormone receptor-positive/human epidermal growth factor receptor-negative advanced or metastatic breast cancer administered at least 1 dose reduction of ribociclib (Kisqali) from the starting dose of 600 mg.

Individuals with elevated arterial stiffness combined with high blood pressure had the highest risk of developing type 2 diabetes.

Natalizumab (Tysarbi) is an integrin receptor antagonist indicated for treatment of: multiple sclerosis and Crohn disease.

Natrol Stress & Anxiety helps decrease the effects of stress and anxiety to aid in establishing normal sleep patterns.

Oncology pharmacists can help ensure patient access to lifesaving therapies.

The FDA approved decitabine/cedazuridine in 2020 for treatment of adults with myelodysplastic syndromes.

The application submission paves the way for a potential decision as early as this month.

Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.

Pharmacists can directly addressing health care disparities among socially disadvantaged and underserved communities.

The gout medicine is a potential treatment option for individuals hospitalized for the cardiovascular condition, analysis suggests.

The findings show that at 90 days, the modified Rankin Score (mRS) had a significantly greater number of individuals with an improvement of 2 points or greater.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

There are a huge number of medical facilities in Ukraine that run international clinical trials, with the FDA noting that more than 250 drugs and devices were undergoing clinical research in Ukraine.

The new study analyzed KSHV’s latent-lytic switch, a process in which the virus exits its dormancy state to replicate in the host cell.